Skip to main content

Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)

Tipranks - Tipranks - Sat Nov 8, 2025

In a report released today, Saket Kalia from Barclays maintained a Buy rating on Omada Health, Inc., with a price target of $29.00.

Meet Your ETF AI Analyst

Kalia covers the Technology sector, focusing on stocks such as Adobe, CrowdStrike Holdings, and Check Point. According to TipRanks, Kalia has an average return of 13.9% and a 64.21% success rate on recommended stocks.

In addition to Barclays, Omada Health, Inc. also received a Buy from Morgan Stanley’s Craig Hettenbach in a report issued on November 3. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Omada Health, Inc. (NASDAQ: OMDA).

See Insiders’ Hot Stocks on TipRanks >>

Based on Omada Health, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $61.37 million and a GAAP net loss of $5.31 million.

Read More on OMDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).